Cargando…
The Effect of the Kirsten Rat Sarcoma Viral Oncogene Homolog (Kras) Proto-Oncogene, GTPase Genetic Polymorphism on the Safety and Efficacy of Bevacizumab Combination Treatment Regimens for Patients with Nonsquamous, Non-Small Cell Lung Cancer with Brain Metastases
BACKGROUND: Non-small cell lung cancer with brain metastasis (NSCLCBM) is normally observed in advanced-stage patients. Bevacizumab has shown to improve survival in the first-line treatment of metastatic brain NSCLC when added as a bolus plus irinotecan. However, a better understanding of the molecu...
Autores principales: | Song, Zizheng, Ren, Guanying, Wang, Xiaolei, Hu, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150132/ https://www.ncbi.nlm.nih.gov/pubmed/35638910 http://dx.doi.org/10.1089/gtmb.2021.0219 |
Ejemplares similares
-
MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation
por: Wang, Yuan, et al.
Publicado: (2015) -
Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis
por: Lin, Zhizun, et al.
Publicado: (2021) -
The proto-oncogene KRAS is targeted by miR-200c
por: Kopp, Florian, et al.
Publicado: (2013) -
Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer
por: Hamilton, Gerhard, et al.
Publicado: (2023) -
Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report
por: Boby, Jeffrey Mathew, et al.
Publicado: (2022)